| ANIXA BIOSCIENCES DL -,01 |
| USA |
| Gesundheit |
| US03528H1095 / A2N6ZF |
| CY71 (Frankfurt) / ANIX (NASDAQ) |
| FRA:CY71, ETR:CY71, CY71:GR, NASDAQ:ANIX |
| - |
| https://www.anixa.com/ |
|
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company develops cancer vaccines and cell-based immunotherapies, including programs centered on breast cancer, ovarian cancer, an..
>Volltext.. |
| 96.31 Mio. EUR |
| 83.73 Mio. EUR |
| - |
| -9.18 Mio. EUR |
| -8.66 Mio. EUR |
| -0.26 EUR |
| 0.16 Mio. EUR |
| 1.27 Mio. EUR |
| -6.14 Mio. EUR |
| 9.12 |
| - |
| 20.17% |
| - |
| - |
| - |
| - |
| ANIXA BIOSCIENCES, ANIXA BIOSCIENCE, ANIXA BIO |
| 08.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|